Clinical significance and expression of microRNA-21 in diffuse large B-cell lymphoma cell lines and serum of patients
Objective: To study the expression of miR-21 in diffuse large B-cell lymphoma (DLBCL) cell lines and serum of patients and validate the significance of miR-21 in early diagnosis, genotyping and prognosis estimates of DLBCL. Methods: miR-21 expression were detected by FQ-PCR in 9 pancreatic cancer cell lines (OCI-Lyk、 OCI-Lv3、OCI-Ly4、 OCI-Ly7、 OCI-Ly8、 OCILylO、 OCI-Lyl8、 OCI-Lyl9、 HBL), then we detected miR-21 expression levels by FQ-PCR in matched tumor tissue and serum from DLBCL patients (n=30). Farther, we detected miR-21 expression levels by FQ-PCR in serum from DLBCL patients (n=62) with health controls (n=50). The IPI score was used to estimate the prognosis of patients with DLBCL. Results: FQ-PCR results indicated miR-21 high expressed in DLBCL cell lines than normal B cells (BC). MiR-21 expression segregates with specific molecular subgroups of DLBCL and it is higher in the ABC subgroup cell lines (OCILy3, OCI-LylO, HBL) than GCB subgroup cell lines (OCI-Lyl, OCI-Ly4, OCI-Ly7, OCI-Ly8, OCI-Lyl8, OCILyl9) (t= 11.18, P<0.0001), and circulating miR-21 expression levels have very good correlation with those that matched tumor tissue in lymphoma cases (r2 =0.931, P<0.0001). Consistent with the cell lines model, miR-21 expression levels were higher in serum from DLBCL patients(51.42±90.29, n=62) than that of control (2.57±2.01, n=50) (t =3.82, P =0.0002), and levels were higher in DLBCL cases with an ABC-type(79.89± 122.38, n=30) than those that were GCB-type (24.73±22.64, n=32) (t=2.51, P=0.015). MiR-21 expression levels were different in serum from DLBCL patients with different clinical stage, higher in DLBCL cases with 1,11 stages than those that of IILIV stages (t =2.28, P =0.03 in GCB type; t =2.58, P = 0.0125 in ABC type). Moreover, high miR-21 expression was associated with relapse-free survival (t=2.19, P=0.035). Conclusion: MiR-21 is high expression in DLBCL cell lines and DLBCL patients serum. Circulating miR-21 level in sera from DLBCL patients was associated with matched tumor tissue, and miR-21 level in sera from DLBCL patients was associated with clinical stage, molecular subgroup, prognosis estimates. miR-21 may serve as a new biomarker to early diagnosis, genotyping, treatment options and prognosis estimating of DLBCL.
DLBCL miRNA early detection biomarkers
CHEN Wei-qun LU Honf-da KONG De-yong LIU Shui-yi TANG Bei-bei Kong Qin-zhi LU Zhong-xin
Department ofMedical Laboratory, Centred Hospital ofWuhan, Wuhan 430014, China Department of Centra Department of Oncology, Central Hospital of Wuhan, Wuhan 430014, China Department ofMedical Laboratory, Centred Hospital ofWuhan, Wuhan 430014, China Department of Central Laboratory, Central Hospital of Wuhan, Wuhan 430014, China Department of Oncol
国际会议
亚太地区国际肿瘤生物学和医学学术会议、全国肿瘤标志学术大会、第六届中国中青年肿瘤专家论坛
上海
英文
105-113
2011-10-13（万方平台首次上网日期，不代表论文的发表时间）